STEP-BY-STEP diagnosis of cardiac amyloidosis: from suspicion to verification
https://doi.org/10.51922/2616-633X.2024.8.2.2328
Abstract
The article analyzes the modern view on the algorithm for the diagnosis of amyloid cardiomyopathy and the role of cardiovascular magnetic resonance imaging in it. A step-by-step diagnosis of AA amyloidosis of the heart is presented using a clinical case as an example. The course of the disease was characterized by worsening of the symptoms of heart failure in combination with persistent increase in troponin levels, pseudo-infarction pattern on the electrocardiogram, and unexplained myocardial hypertrophy according to echocardiography. In order to clarify the nature of the myocardial damage, a cardiovascular MRI was performed, the results of which revealed signs of storage disease. In order to confirm amyloidosis, a histological examination of a biopsy of the oral mucosa was performed.
About the Authors
A. A. Bondareva
City Clinical Hospital of Emergency Medical Care
Belarus
Belarus
Minsk
E. M. Balysh
Belarusian State Medical University
Belarus
Belarus
Minsk
T. V. Statkevich
Belarusian State Medical University
Belarus
Belarus
Minsk Minsk
E. B. Petrova
Belarusian State Medical University
Belarus
Belarus
Minsk
O. M. Shabunevich
City Clinical Hospital of Emergency Medical Care
Belarus
Belarus
Minsk
D. S. Moiseenko
City Clinical Hospital of Emergency Medical Care
Belarus
Belarus
Minsk
N. B. Kononchuk
Belarusian State Medical University
Belarus
Belarus
Minsk
References
1. Arbelo E., Protonotarios A., Gimeno J. R. уt al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J, 2023, vol. 44(37), pp. 3503–3626. doi: 10.1093/eurheartj/ehad194.
2. Garcia-Pavia P., Rapezzi Cl., Adler Y. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 2021, vol. 42(16), pp. 1554-1568. doi: 10.1093/eurheartj/ehab072.
3. Quock T. P., Yan T., Chang E. et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv, 2018, vol. 2(10), pp. 1046-1053. doi: 10.1093/eurheartj/ehab072.
4. Rameev V.V., Moiseev S.V., Kozlovskaya L.V. AA-amyloidosis in autoinflammatory diseases. Clinical pharmacology and therapy, 2021, vol. 30(4), pp. 52-61. (in Russian).
5. Brunger A.F., Nienhuis H.L.A., Bijzet J., Hazenberg B.P.C. Causes of AA amyloidosis: a systematic review. Amyloid, 2020, vol. 27(1), pp. 1-12. doi: 10.1080/13506129.2019.1693359.
6. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med, 2003, vol. 349(6), pp. 583-596. doi: 10.1056/NEJMra023144.
7. Reznik E.V., Nguyen T.L., Stepanova E.A., Ustyuzhanin D.V., Nikitin I.G. Cardiac amyloidosis: internist and cardiologist insight. Archive of internal medicine, 2020, vol. 10(6), pp. 430-456. doi: 10.20514/2226-6704-2020-10-6-430-457. (in Russian).
8. Mohtya D., Damyc T., Cosnay P. et al. Cardiac amyloidosis: Updates in diagnosis and management. Arch Cardiovasc Dis, 2013, vol. 106(10), pp. 528-540. doi: 10.1016/j.acvd.2013.06.051.
9. Kittleson M.M., Maurer M.S., Ambardekar A.V. et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation, 2020, vol. 142(1), pp. e7-e22. doi: 10.1161/CIR.0000000000000792.
10. Fitzgerald B.T., Scalia G.M., Cain P.A. et al. Left atrial size-Another Differentiator for Cardiac Amyloidosis. Heart Lung Circ, 2011, vol. 20(9), pp. 574-578. doi: 10.1016/j.hlc.2011.06.002.
11. Oda S., Kidoh M., Nagayam Y. et al. Trends in Diagnostic Imaging of Cardiac Amyloidosis: Emerging Knowledge and Concepts. Radiographics, 2020, vol. 40(4), pp. 961-981. doi: 10.1148/rg.2020190069.
12. Vogelsberg H., Mahrholdt Н., Deluigi C. et al. Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis: Noninvasive Imaging Compared to Endomyocardial Biopsy. J Am Coll Cardiol, 2008, vol. 51(10), pp. 1022-1030. doi: 10.1016/j.jacc.2007.10.049.
13. Mohammed S.F., Mirzoyev S.A., Edwards W.D. et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail, 2014, vol. 2(2), pp. 113-22. doi: 10.1016/j.jchf.2013.11.004.
14. Mircsof D. Diagnosis of Amyloidosis: A Survey of Current Awareness and Clinical Challenges Among Cardiologists in Switzerland. Cardiol Ther, 2020, vol. 9(1), pp. 127-138. doi: 10.1007/s40119-019-00160-8
Review
For citations:
Bondareva A.A., Balysh E.M., Statkevich T.V., Petrova E.B., Shabunevich O.M., Moiseenko D.S., Kononchuk N.B. STEP-BY-STEP diagnosis of cardiac amyloidosis: from suspicion to verification. Emergency Cardiology and Cardiovascular Risks journal. 2024;8(2):2328–2336. (In Russ.) https://doi.org/10.51922/2616-633X.2024.8.2.2328
Views:
9
Email this article 